Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years

Hely, Mariese A., Morris, John G.L., Reid, Wayne G.J., Trafficante, Robert·2005·Movement Disorders
DOI 10.1002/mds.20324

Cited by (1,000)

Items 301–400 of 1,000

  1. L-745,870 Reduces l-DOPA-Induced Dyskinesia in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease
    Philippe Huot, Tom H. Johnston, James B. Koprich, Ahmed M. Aman, Susan Helen Fox, Jonathan M. Brotchie · 2012 · Journal of Pharmacology and Experimental Therapeutics
  2. Anatomically Selective Serotonergic Type 1A and Serotonergic Type 2A Therapies for Parkinson’s Disease: An Approach to Reducing Dyskinesia without Exacerbating Parkinsonism?
    Philippe Huot, Susan Helen Fox, Adrian Newman‐Tancredi, Jonathan M. Brotchie · 2011 · Journal of Pharmacology and Experimental Therapeutics
  3. The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset
    Adjia Hamadjida, Stephen G. Nuara, Nicolas Veyres, Imane Frouni, Cynthia Kwan, Lamia Sid‐Otmane, Mery-Jane Harraka, Jim C. Gourdon, Philippe Huot · 2017 · Psychopharmacology
  4. Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson’s Disease
    Mark D. Latt, Simon J.G. Lewis, Olfat Zekry, Victor S.C. Fung · 2019 · Drugs & Aging
  5. Depression in Parkinson's disease: Perspectives from an Australian cohort
    Michal Lubomski, Ryan L. Davis, Carolyn M. Sue · 2020 · Journal of Affective Disorders
  6. On‐Demand Therapy for OFF Episodes in Parkinson's Disease
    C. Warren Olanow, Werner H Poewe, Olivier Rascol, Fabrizio Stocchi · 2021 · Movement Disorders
  7. Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque
    Philippe Huot, Tom H. Johnston, James B. Koprich, Lieke Winkelmolen, Susan Helen Fox, Jonathan M. Brotchie · 2010 · Neurobiology of Aging
  8. UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances l-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset
    Philippe Huot, Tom H. Johnston, Katie D. Lewis, James B. Koprich, M. Gabriela Reyes, Susan Helen Fox, Matthew Piggott, Jonathan M. Brotchie · 2014 · Neuropharmacology
  9. Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta‐analysis of levodopa‐controlled trials
    Maria Chondrogiorgi, Athina Tatsioni, Heinz Reichmann, Spyridon Konitsiotis · 2013 · European Journal of Neurology
  10. Medication Therapy Management Service for Patients with Parkinson’s Disease: A Before-and-After Study
    Aline Aparecida Foppa, Clarice Chemello, Claudia Marcela Vargas-Peláez, Mareni Rocha Farías · 2016 · Neurology and Therapy
  11. Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update.
    P. Huot, Véronique Sgambato-Faure, S. Fox, A. McCreary · 2017 · ACS Chemical Neuroscience
  12. The highly selective 5-HT2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the l-DOPA-treated parkinsonian marmoset
    Adjia Hamadjida, Stephen G. Nuara, Dominique Bédard, Fleur Gaudette, Francis Beaudry, Jim C. Gourdon, Philippe Huot · 2018 · Neuropharmacology
  13. EEG Microstates Change in Response to Increase in Dopaminergic Stimulation in Typical Parkinson’s Disease Patients
    José Ignacio Serrano, María Dolores del Castillo, Verónica Cortés, Nuno Mendes, Aída Arroyo-Ferrer, Jorge Andreo-Jover, Eduardo Rocón, Maria Del Valle, Jaime Herreros Rodríguez, Juan Pablo Romero · 2018 · Frontiers in Neuroscience
  14. Treatment options for postural instability and gait difficulties in Parkinson’s disease
    Martijn L.T.M. Müller, Uroš Marušič, Miriam van Emde Boas, Daniel Weiß, Nicolaas Ida Bohnen · 2019 · Expert Review of Neurotherapeutics
  15. Treatment of advanced Parkinson’s disease
    Alan L. Diamond, Joseph J. Jankovic · 2006 · Expert Review of Neurotherapeutics
  16. Mapping Cortical Atrophy in Parkinson's Disease Patients with Dementia
    Kristy Hwang, Mona Kristiansen Beyer, Amity E. Green, Christine Chung, Paul M. Thompson, Carmen Cristea Janvin, Jan Otto Larsen, Dag Aarsland, Liana G. Apostolova · 2013 · Journal of Parkinson s Disease
  17. Enfermedad de Parkinson avanzada. Características clínicas y tratamiento. Parte II
    Jaime Kulisevsky, M. R. Luquín, José Matías Arbelo, Juan Andrés Burguera, F. Carrillo, A. Castro, J. Chacón, Pedro Ruiz, E. Lezcano, Pablo Mir et al. · 2013 · Neurología
  18. The highly-selective 5-HT1A agonist F15599 reduces l-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque
    Philippe Huot, Tom H. Johnston, Susan Helen Fox, Adrian Newman‐Tancredi, Jonathan M. Brotchie · 2015 · Neuropharmacology
  19. Contemporary Options for the Management of Motor Complications in Parkinson’s Disease: Updated Clinical Review
    Verónica Cabreira, Patrı́cio Soares-da-Silva, João Massano · 2019 · Drugs
  20. Mortality in Levodopa-Treated Parkinson's Disease
    John C. Morgan, Lillian J. Currie, Madaline B. Harrison, James P. Bennett, Joel M. Trugman, G. Frederick Wooten · 2014 · Parkinson s Disease
  21. Complementary & Alternative Management of Parkinson’s Disease: An Evidence-Based Review of Eastern Influenced Practices
    Danny Bega, Cindy Zadikoff · 2014 · Journal of Movement Disorders
  22. Activation of mGlu2/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism
    Imane Frouni, Adjia Hamadjida, Cynthia Kwan, Dominique Bédard, Vaidehi Nafade, Fleur Gaudette, Stephen G. Nuara, Jim C. Gourdon, Francis Beaudry, Philippe Huot · 2019 · Neuropharmacology
  23. Incoming ethical issues for deep brain stimulation: when long-term treatment leads to a ‘new form of the disease’
    Frédéric Gilbert, Mathilde Lancelot · 2020 · Journal of Medical Ethics
  24. Parkinson’s Disease: Cognitive Impairment
    Joel Mack, Laura Marsh · 2017 · FOCUS The Journal of Lifelong Learning in Psychiatry
  25. Palliative Care in Parkinson’s Disease
    Janis M. Miyasaki · 2013 · Current Neurology and Neuroscience Reports
  26. Residual striatal dopaminergic nerve terminals in very long‐standing Parkinson's disease: A single photon emission computed tomography imaging study
    Ruth Djaldetti, Mordechai Lorberboym, Yuval Karmon, Therese A. Treves, Ilan Ziv, Eldad Melamed · 2010 · Movement Disorders
  27. The Monoamine Re-Uptake Inhibitor UWA-101 Improves Motor Fluctuations in the MPTP-Lesioned Common Marmoset
    Philippe Huot, Tom H. Johnston, Michael N. Gandy, M. Gabriela Reyes, Susan Helen Fox, Matthew Piggott, Jonathan M. Brotchie · 2012 · PLoS ONE
  28. Near-falls in people with Parkinson's disease: Circumstances, contributing factors and association with falling
    Tatjana M. Gazibara, Darija Kisić-Tepavčević, Marina V. Svetel, Aleksandra Tomić, Iva Stanković, Vladimir Kostić, Tatjana D. Pekmezovic · 2017 · Clinical Neurology and Neurosurgery
  29. Critical appraisal of pathology transmission in the α-synuclein fibril model of Lewy body disorders
    Negin Nouraei, Daniel M. Mason, Kristin M. Miner, Michael A. Carcella, Tarun N. Bhatia, Benjamin K. Dumm, Dishaben Soni, David A. Johnson, Kelvin C. Luk, Rehana K. Leak · 2017 · Experimental Neurology
  30. Levodopa Effect and Motor Function in Late Stage Parkinson’s Disease
    Kristina Rosqvist, Malcolm Kenneth Horne, Peter Hagell, Susanne Iwarsson, Maria H Nilsson, Per Odin · 2018 · Journal of Parkinson s Disease
  31. Behavioral and cellular dopamine D1 and D3 receptor-mediated synergy: Implications for L-DOPA-induced dyskinesia
    Kathryn Lanza, Samantha M. Meadows, Nicole Chambers, Emily Nuss, Molly M. Deak, Sergi Ferré, Christopher Bishop · 2018 · Neuropharmacology
  32. Structural Brain Correlations of Visuospatial and Visuoperceptual Tests in Parkinson’s Disease
    Garcia-Diaz, Anna Isabel, Segura, Barbara, Baggio, Hugo Cesar, Marti, Maria Jose, Valldeoriola, Francesc, Compta, Yaroslau, Bargallo, Nuria, Uribe, Carme, Campabadal, Anna, Abos, Alexandra et al. · 2018 · Journal of the International Neuropsychological Society
  33. Monoamine Reuptake Inhibitors in Parkinson’s Disease
    Philippe Huot, Susan Helen Fox, Jonathan M. Brotchie · 2015 · Parkinson s Disease
  34. Lewy Body Dementias
    Melissa J. Armstrong · 2019 · CONTINUUM Lifelong Learning in Neurology
  35. Morbidity and mortality in orthostatic hypotension
    Maureen Farrell, Cyndya A. Shibao · 2020 · Autonomic Neuroscience
  36. Maintaining balance against force perturbations: impaired mechanisms unresponsive to levodopa in Parkinson's disease
    Irene Di Giulio, Rebecca J. St George, Eirini Kalliolia, Amy Peters, Patricia Dowsey Limousin, Brian L. Day · 2016 · Journal of Neurophysiology
  37. Parkinson’s Disease Related Depression and Anxiety: A 22-Year Bibliometric Analysis (2000-2022)
    Tong Zhang, Rui Yang, Juhua Pan, Shijing Huang · 2023 · Neuropsychiatric Disease and Treatment
  38. Diagnosing Parkinson Disease
    Christopher W. Hess, Michael S. Okun · 2016 · CONTINUUM Lifelong Learning in Neurology
  39. Mortality from Parkinson's disease in China: Findings from a ten-year follow up study in Shanghai
    Yueqi Zhang, Chunfang Wang, Ying Wang, Qin Xiao, Jun Liu, Jianfang Ma, Haiyan Zhou, Jing Pan, Yuyan Tan, Shengdi Chen et al. · 2018 · Parkinsonism & Related Disorders
  40. l ‐3,4‐dihydroxyphenylalanine ( l ‐DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha‐synuclein mouse models of Parkinson's disease
    Jessica L. Billings, Sarah L. Gordon, Tristan Rawling, Philip Doble, Ashley Ian Bush, Paul Anthony Adlard, David Isaac Finkelstein, Dominic James Hare · 2019 · Journal of Neurochemistry
  41. Association of Motor and Cognitive Symptoms with Health-Related Quality of Life and Caregiver Burden in a German Cohort of Advanced Parkinson’s Disease Patients
    Martin Klietz, Theresa Schnur, Simon C. Drexel, Florian Lange, A. Tulke, L. Rippena, Lejla Paracka, Dirk W. Dressler, Günter U. Höglinger, Florian Wegner · 2020 · Parkinson s Disease
  42. Insulin-like growth factor 2 and autophagy gene expression alteration arise as potential biomarkers in Parkinson’s disease
    Denisse Sepúlveda, Felipe Grünenwald, Alvaro Vidal, Paulina Troncoso-Escudero, Marisol Cisternas-Olmedo, Roque Villagra, Pedro Vergara, Carlos Aguilera, Melissa Nassif, René L. Vidal · 2022 · Scientific Reports
  43. Parkinson Disease Signaling Pathways, Molecular Mechanisms, and Potential Therapeutic Strategies: A Comprehensive Review
    M. S. Khan, Somayyeh Nasiripour, Jean C. Bopassa · 2025 · International Journal of Molecular Sciences
  44. Evaluation of non-motor symptoms in Parkinson's Disease: An underestimated necessity.
    Sevasti Bostantjopoulou, Zoe Katsarou, Charalambos Karakasis, Eleni Peitsidou, D Milioni, N Rossopoulos · 2013 · Europe PMC (PubMed Central)
  45. Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease
    Kentaro Hirao, Gregory M. Pontone, Gwenn S. Smith · 2014 · Neuroscience & Biobehavioral Reviews
  46. Dysphagia in Parkinson’s disease: a therapeutic challenge?
    Emilia Michou, Shaheen Hamdy · 2010 · Expert Review of Neurotherapeutics
  47. STN versus GPi deep brain stimulation for dyskinesia improvement in advanced Parkinson’s disease: A meta-analysis of randomized controlled trials
    Junhuai Zhang, Jiayu Li, Chen Fang, Xingzhi Liu, Chun Jiang, Xinghua Hu, Lin Ma, Zhongye Xu · 2020 · Clinical Neurology and Neurosurgery
  48. Neuropsychiatric and Cognitive Deficits in Parkinson’s Disease and Their Modeling in Rodents
    Mélina Decourt, Haritz Jiménez‐Urbieta, Marianne Benoit‐Marand, Pierre‐Olivier Fernagut · 2021 · Biomedicines
  49. Effect of Intrastriatal 6-OHDA Lesions on Extrastriatal Brain Structures in the Mouse
    Birte Becker, Melek Demirbas, Sonja Johann, Adib Zendedel, Cordian Beyer, Hans Clusmann, Stefan Jean-Pierre Haas, Andreas Wree, Sonny K. H. Tan, Markus Kipp · 2017 · Molecular Neurobiology
  50. Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist
    Jinglin Zhang, Louis C.S. Tan · 2016 · Current Neuropharmacology
  51. Subthalamic deep brain stimulation modulates conscious perception of sensory function in Parkinson's disease
    Rubens Gisbert Cury, Ricardo Galhardoni, Manoel Jacobsen Teixeira, Maria Gabriela dos Santos Ghilardi, Valquíria Aparecida da Silva, Martin Luiz Myczkowski, Marco Antônio Marcolin, Egberto Reis Barbosa, Erich Talamoni Fonoff, Daniel Ciampi de Andrade · 2016 · Pain
  52. Interdisciplinary palliative care for people with advanced Parkinson’s disease: a view from the home
    Jori Erin Fleisher, Ellen C. Klostermann, Serena Hess, Jeanette Lee, Erica Myrick, Joshua Chodosh · 2019 · Annals of Palliative Medicine
  53. Subjective cognitive decline in idiopathic Parkinson´s disease: A systematic review
    Christiane Oedekoven, Leonie Egeri, Frank Jessen, Michael Wagner, Richard C. Dodel · 2021 · Ageing Research Reviews
  54. The Aging Brain and Neurodegenerative Diseases
    Gary W. Duncan · 2011 · Clinics in Geriatric Medicine
  55. Overexpression of the dopamine D3 receptor in the rat dorsal striatum induces dyskinetic behaviors
    Samantha Rae Cote, Vineet Chandra Chitravanshi, Carina J. Bleickardt, Hreday N. Sapru, Eldo V. Kuzhikandathil · 2014 · Behavioural Brain Research
  56. Controversies in Neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease
    Matthias Löhle, Heinz Reichmann · 2011 · BMC Neurology
  57. Management of Parkinson???s Disease Dementia
    Arvid Rongve, Dag Aarsland · 2006 · Drugs & Aging
  58. Variants in the SNCA gene associate with motor progression while variants in the MAPT gene associate with the severity of Parkinson's disease
    Gang Wang, Yue Ming Huang, Wei Chen, Daiwen Chen, Ying Wang, Qin Xiao, Jun Liu, Victor S.C. Fung, Glenda Margaret Halliday, Shengdi Chen · 2015 · Parkinsonism & Related Disorders
  59. Sensor-based gait analysis of individualized improvement during apomorphine titration in Parkinson’s disease
    Franz Marxreiter, Heiko Gaßner, Olga Borozdina, Jens Barth, Zacharias Kohl, Johannes C. M. Schlachetzki, Caroline Thun-Hohenstein, Dieter Volc, Bjoern M. Eskofier, Jürgen Winkler et al. · 2018 · Journal of Neurology
  60. Review: Clinical, neuropathological and genetic features of Lewy body dementias
    Daniela Hansen, Helen Ling, Tammaryn Lashley, Janice L. Holton, Thomas T. Warner · 2019 · Neuropathology and Applied Neurobiology
  61. An overview of the effects of levodopa and dopaminergic agonists on sleep disorders in Parkinson’s disease
    Amanda Scanga, Anne‐Louise Lafontaine, Marta Kamińska · 2023 · Journal of Clinical Sleep Medicine
  62. Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson's disease patients as assessed by the Non-Motor Symptoms Questionnaire.
    David Crosiers, Barbara Anne Pickut, Jessie Theuns, Peter Paul De Deyn, Christine Van Broeckhoven, Pablo Martínez‐Martín, К. Ray Chaudhuri, Patrick P Cras · 2012 · Europe PMC (PubMed Central)
  63. Defining disease‐modifying therapies for PD—A road map for moving forward
    C. Warren Olanow, Karl D. Kieburtz · 2010 · Movement Disorders
  64. Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues
    Joseph Claßen, Jiri Koschel, Christian Oehlwein, Klaus Seppi, Peter Paul Urban, Christian Winkler, Ullrich Wüllner, Alexander Storch · 2017 · Journal of Neural Transmission
  65. An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele
    Marian Shahid, Jeehyun Kim, Katherine R. Leaver, Taylor R. Hendershott, Delphine Zhu, Brenna Cholerton, Victor W. Henderson, Lü Tian, Kathleen L. Poston · 2019 · Neurobiology of Disease
  66. How to optimize the treatment of early stage Parkinson’s disease
    Fabrizio Stocchi, Laura Vacca, Fabiana Giada Radicati · 2015 · Translational Neurodegeneration
  67. External validation of a 3-step falls prediction model in mild Parkinson’s disease
    Beata Lindholm, Maria H Nilsson, Oskar Hansson, Peter Hagell · 2016 · Journal of Neurology
  68. Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease
    Tom H. Johnston, Alix M.B. Lacoste, Naomi P. Visanji, Anthony Edward Lang, Susan Helen Fox, Jonathan M. Brotchie · 2018 · Neuropharmacology
  69. Neural Correlates of Cognitive Impairment in Parkinson's Disease: A Review of Structural MRI Findings
    Julie M. Hall, Simon J.G. Lewis · 2018 · International review of neurobiology
  70. Shedding Light on Nocturnal Movements in Parkinson’s Disease: Evidence from Wearable Technologies
    Alessandro Zampogna, Alessandro Manoni, Francesco Asci, Claudio Liguori, Fernanda Irrera, Antonio Suppa · 2020 · Sensors
  71. New non-oral drug delivery systems for Parkinson's disease treatment
    Shadab Md, Shadabul Haque, Jasjeet Kaur Sahni, Sanjula Baboota, Javed Ali · 2011 · Expert Opinion on Drug Delivery
  72. Validation of a Psycho-Sensory hAllucinations Scale (PSAS) in schizophrenia and Parkinson's disease
    I. de Chazeron, B. Pereira, Isabelle Chéreau, Georges Brousse, David Misdrahi, Gilles Fénelon, Anne-Marie Tronche, Raymund Schwan, Christophe Lançon, Ana Marquès et al. · 2014 · Schizophrenia Research
  73. Nonmotor symptom complex of Parkinson's disease--an under-recognized entity.
    Manmohan Mehndiratta, Rohit Garg, Sanjay Pandey · 2011 · PubMed
  74. Symptom Prevalence among People Affected by Advanced and Progressive Neurological Conditions—a Systematic Review
    Tariq Saleem, P. Nigel Leigh, Irene J Higginson · 2007 · Journal of Palliative Care
  75. PARK10 Candidate RNF11 Is Expressed by Vulnerable Neurons and Localizes to Lewy Bodies in Parkinson Disease Brain
    Leah R. Anderson, Ranjita S. Betarbet, Marla Gearing, Jeffrey R. Gulcher, Andrew A. Hicks, Kāri Stefánsson, James J. Lah, Allan I. Levey · 2007 · Journal of Neuropathology & Experimental Neurology
  76. The incidence and risk factors of falls in Parkinson disease: prospective study
    Monika Rudzińska, Sylwia Bukowczan, Joanna Stożek, Katarzyna Zajdel, Elżbieta Mirek, Wiesław Chwała, Magdalena Wójcik-Pędziwiatr, Krzysztof Banaszkiewicz, Andrzej Szczudlik · 2013 · Neurologia i Neurochirurgia Polska
  77. Neurorehabilitation in Parkinson disease
    Neil K. Archibald, Nick Miller, Lynn Rochester · 2013 · Handbook of clinical neurology
  78. Classic animal models of Parkinson’s disease: a historical perspective
    Adjia Hamadjida, Imane Frouni, Cynthia Kwan, Philippe Huot · 2018 · Behavioural Pharmacology
  79. Parkinson’s Disease Dementia
    Mary Jane Docherty, David John Burn · 2010 · Current Neurology and Neuroscience Reports
  80. Perceptions of people living with Parkinson's disease: a qualitative study in Iran
    Mohammad Ali Soleimani, Farideh Bastani, Reza Negarandeh, Ryan Greysen · 2016 · British Journal of Community Nursing
  81. Long-term risk of falls in an incident Parkinson’s disease cohort: the Norwegian ParkWest study
    Ylva Hivand Hiorth, Guido Werner Alves, Jan Petter Larsen, Jörn Schulz, Ole‐Bjørn Tysnes, Kenn Freddy Pedersen · 2016 · Journal of Neurology
  82. Key clinical milestones 15 years and onwards after DBS-STN surgery—A retrospective analysis of patients that underwent surgery between 1993 and 2001
    Radu Constantinescu, Barbro Eriksson, Yvonne Jansson, Bo Johnels, Björn Holmberg, Thordis Gudmundsdottir, Annika Renck, Peter Berglund, Filip Bergquist · 2017 · Clinical Neurology and Neurosurgery
  83. The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset
    Adjia Hamadjida, Stephen G. Nuara, Jim C. Gourdon, Philippe Huot · 2017 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  84. Nabilone for non-motor symptoms of Parkinson’s disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study)
    Marina Peball, Mario Werkmann, Philipp Ellmerer, Raphaela Stolz, Dora Valent, Hans‐Günther Knaus, Hanno Ulmer, Atbin Djamshidian, Werner H Poewe, Klaus Seppi · 2019 · Journal of Neural Transmission
  85. Parkinson disease
    Samuel D. Kim, Natalie Elizabeth Allen, Colleen G. Canning, Victor S.C. Fung · 2018 · Handbook of clinical neurology
  86. Assessment and treatment of neurogenic dysphagia in stroke and Parkinson's disease
    Giuseppe Cosentino, Massimiliano Todisco, Carla Giudice, Cristina Tassorelli, Enrico Alfonsi · 2022 · Current Opinion in Neurology
  87. Gait disturbances in Parkinson disease. Did freezing of gait exist before levodopa? Historical review
    Pedro Ruiz · 2011 · Journal of the Neurological Sciences
  88. Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson’s disease
    Adjia Hamadjida, Stephen G. Nuara, Jim C. Gourdon, Philippe Huot · 2017 · Journal of Neural Transmission
  89. A multimodal dataset of real world mobility activities in Parkinson’s disease
    Catherine Morgan, Emma L. Tonkin, Alessandro Masullo, Ferdian Jovan, Arindam Sikdar, Pushpajit Khaire, Majid Mirmehdi, Ryan McConville, Gregory J. L. Tourte, Alan L. Whone et al. · 2023 · Scientific Data
  90. Motor learning in animal models of Parkinson's disease: Aberrant synaptic plasticity in the motor cortex
    Tonghui Xu, Shaofang Wang, Rupa R. Lalchandani, Jun Ding · 2017 · Movement Disorders
  91. Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease.
    E. D. de Natale, F. Niccolini, H. Wilson, M. Politis · 2018 · International review of neurobiology
  92. The effect of STN DBS on modulating brain oscillations: consequences for motor and cognitive behavior
    Fabian J. David, Miranda J. Munoz, Daniel M. Corcos · 2020 · Experimental Brain Research
  93. Physical assessment as a predictor of mortality in people with Parkinson's disease: A study over 7 years
    William K. Gray, Anthony John Hildreth, Julie A. Bilclough, Brian H. Wood, Katherine Baker, Richard William Walker · 2009 · Movement Disorders
  94. An electromyographic study of parkinsonian swallowing and its response to levodopa
    Paul B. Tawadros, Dennis John Cordato, Ian Cathers, John A. Burne · 2012 · Movement Disorders
  95. Frequency of non-motor symptoms in Parkinson’s disease presenting to tertiary care centre in Pakistan: an observational, cross-sectional study
    Shahid M. Mukhtar, Rashid Imran, Mohsin Zaheer, Huma Tariq · 2018 · BMJ Open
  96. Improvement of Deep Brain Stimulation in Dyskinesia in Parkinson's Disease: A Meta-Analysis
    Yun Liu, Feng Li, Hansheng Luo, Qiuguang He, Lifen Chen, Yuan Zeng Cheng, Wenbin Zhang, Zongyi Xie · 2019 · Frontiers in Neurology
  97. Neuropathology of Parkinson’s Disease
    K. A. Jellinger · 2014 · Springer eBooks
  98. Non-Motor Off Symptoms in Parkinson's Disease
    Sang‐Myung Cheon, Minjeong Park, Wook-Joo Kim, Jae Woo Kim · 2009 · Journal of Korean Medical Science
  99. ADORA2A rs5760423 and CYP1A2 rs762551 Polymorphisms as Risk Factors for Parkinson’s Disease
    Siokas, Vasileios, Aloizou, Athina-Maria, Tsouris, Zisis, Liampas, Ioannis, Liakos, Panagiotis, Calina, Daniela, Docea, Anca Oana, Tsatsakis, Aristidis, Bogdanos, Dimitrios P., Hadjigeorgiou, Georgios M. et al. · 2021 · Journal of Clinical Medicine
  100. Neurotrophic Factors and Neurodegenerative Diseases
    Barbara Ruozi, Daniela Belletti, Lucia Bondioli, Alessandro De Vita, Flavio Forni, Maria Angela Vandelli, Giovanni Tosi · 2012 · International review of neurobiology